Unraveling the safety and efficacy of semaglutide for people living with HIV and metabolic co-morbidities.

The article addresses the increasing prevalence of metabolic dysregulation among people living with HIV (PLWH). Topics include the rising rates of obesity and diabetes mellitus in PLWH, the risk factors contributing to metabolic dysfunction, and the impact of antiretroviral therapy (ART) on the development of related co-morbidities like metabolic dysfunction-associated steatotic liver disease (MASLD).